Overview
Endeavor Health is seeking volunteers for a new research study exploring whether a medicine called adalimumab can help men with benign prostatic hyperplasia (BPH), also known as an enlarged prostate. Adalimumab is commonly used to treat conditions where the immune system attacks the body. This study will look at whether the medicine can reduce symptoms, shrink the prostate, or lower inflammation.
BPH is common: about half of men ages 51 to 60 have BPH, and the number rises to about 80% in men over 70. BPH can cause uncomfortable symptoms like frequent urination, pain or difficulty when urinating, waking at night to use the bathroom, feeling like your bladder doesn’t fully empty and leaking urine by accident.
Participants in the study will answer health questions and surveys while getting six treatments every two weeks.
- Men, ages 45-80
- Diagnosed with benign prostatic hyperplasia (BPH) by a physician
- No prior treatment with a tumor necrosis factor (TNF) inhibitor (e.g., adalimumab)
- Able to read, write, and speak English
- Reside in the Chicago area and plan to remain for the next six months
